Evaluation of T follicular regulatory cells as novel cellular targets of cancer immunotherapy
滤泡调节性 T 细胞作为癌症免疫治疗新细胞靶点的评估
基本信息
- 批准号:10737557
- 负责人:
- 金额:$ 10.25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-07-01 至 2023-11-30
- 项目状态:已结题
- 来源:
- 关键词:ATAC-seqAdoptive TransferAffectAntibodiesAntigensAntitumor ResponseAutomobile DrivingCD8-Positive T-LymphocytesCTLA4 geneCellsCellular immunotherapyColitisColonCombined Modality TherapyDNA BindingDataDevelopmentDoseEnhancersEpithelial CellsEvaluationExhibitsFrequenciesGene Expression ProfileGenerationsGenesGenetic EngineeringGenetic TranscriptionHalf-LifeHumanImmuneImmunologyImmunosuppressionImmunotherapyImpairmentInfiltrationLinkMaintenanceMalignant NeoplasmsModelingMolecularMusNatureNeoadjuvant TherapyNon-MalignantOrganPathogenicityPathway interactionsPatientsPhosphatidylinositolsPhosphotransferasesPlacebo ControlPrimary NeoplasmPropertyRandomizedRegimenRegulatory T-LymphocyteRoleSkinSolidSolid NeoplasmT cell responseT-Lymphocyte SubsetsTestingTherapeuticTissuesToxic effectTranslatingTreatment EfficacyTumor ImmunityTumor Tissueanti-CTLA4anti-PD1 therapyantitumor effectcancer immunotherapycancer typecell typecellular targetingchromatin immunoprecipitationcohortdraining lymph nodegastrointestinal epitheliumgenetic approachimmune checkpoint blockadeimmune-related adverse eventsimmunoregulationimprovedin vivoinhibitorinsightkeratinocytemelanomamouse modelneoantigensnovelpharmacologicphase II trialprecursor cellprogrammed cell death protein 1programsprotein expressionresponsesecondary lymphoid organselective expressionsingle-cell RNA sequencingstandard carestemsurvival outcometargeted treatmenttertiary lymphoid organtherapy developmenttranscription factortranscriptomicstumortumor growthtumor microenvironment
项目摘要
Project Summary
Immune checkpoint blockade (ICB) targeting CTLA-4 or PD-1 rapidly assumed its role as a standard treatment
for solid tumors and can lead to dramatic, long-lasting responses; nonetheless, fewer than 30% of patients
respond to monotherapy with either agent. Combination therapy results in better long-term survival outcomes,
but also causes more frequent and severe immune-related adverse events (irAEs). Several novel
immunotherapies are currently being explored to evaluate their anti-tumor capacity. Crucially however, most of
these targets suffer from on-target, off-cell effects, as other immune cell types can express high levels of these
molecules. Hence, as low overall response rates, off-cell effects and widespread immune related toxicity severely
limit both treatment efficacy and monotherapy and combination therapy options, there is urgent need to develop
novel immunotherapy targets that exhibit a more restricted expression profile. We have recently demonstrated
that PD-1+ follicular regulatory T (TFR) cells were prevalent in tumor tissues of several cancer types in humans
and mice, and that they were critical cellular determinants of anti-PD-1 treatment efficacy. TFR cells were primarily
located within tertiary lymphoid structures (TLS) and exhibited superior suppressive capacity and in vivo
persistence when compared to regulatory T (TREG) cells, suggesting a key role for TFR cells in impairing patient
survival and impeding immunotherapy treatment efficacy. While we have shown that intratumoral TFR cells derive
from TREG precursor cells, the mechanisms and transcription factors (TFs) that are driving this differentiation step
are largely unknown. In Aim1, we propose to employ single-cell RNA-seq, single-cell ATAC-seq and micro-
scaled ChIP assays to fully characterize the transcriptomic signatures of tumor-infiltrating TREG cells, transitioning
(4-1BB+) TREG cells and TFR cells. Elucidating the enhancer profiles in different developmental stages of TREG to
TFR differentiation is likely to provide crucial insights into the TFs that instruct this differentiation step. These
analyses will define genes and TFs that are pivotal for the heightened suppressive capacity of TFR cells, as well
as for their maintenance or differentiation. Strategies to deplete TREG cells or to curb their functionality with the
aim of enhancing anti-tumor immunity are being intensively investigated. Crucially however, most of these
approaches are based on antibodies (i.e., ADCC-optimized for TREG cell depletion; i.e. anti-CTLA-4), which have
an inherently long half-life in vivo, thus increasing the likelihood of causing irAEs. Conversely, our data imply that
alternative dosing regimens of Phosphoinositide 3-kinase δ (PI3Kδ) inhibitors might offer a pathway to target TFR
cells more specifically. We propose that PI3Kδ represents a novel and appealing immunotherapy target in solid
tumors. In Aim 2 and Aim 3, we will assess whether alternative dosing regimens of PI3Kd inhibitors can be
utilized to effectively and safely exploit the immunomodulatory impact of PI3Kδ inhibitors in solid cancers and
whether a transient depletion or inhibition of TFR cells might suffice to restrict the immunosuppressive milieu in
the tumor and thus drive anti-tumor immunity without causing toxicity.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Simon Eschweiler其他文献
Simon Eschweiler的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 10.25万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 10.25万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 10.25万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 10.25万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 10.25万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 10.25万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 10.25万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 10.25万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 10.25万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 10.25万 - 项目类别:














{{item.name}}会员




